|
EP2981255B1 |
14 Sep, 2022
|
Therapeutic Uses Of Empagliflozin
|
Apr, 2034
|
10
| |
|
EP2397142B1 |
27 Jul, 2022
|
Use Of Dpp Iv Inhibitors
|
May, 2027
|
5
| |
|
EP2986304B1 |
12 Jan, 2022
|
Pharmaceutical Composition, Methods For Treating And Uses Thereof
|
Apr, 2034
|
4
| |
|
EP2285410B1 |
26 Sep, 2018
|
Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation
|
Apr, 2029
|
4
| |
|
EP2994125B1 |
01 Aug, 2018
|
Efficacious Treatment Of Nsclc And Predictive Clinical Marker Of The Responsiveness Of A Tumour To A Treatment
|
May, 2034
|
4
| |
|
EP2482812B1 |
11 Jan, 2023
|
Therapeutic Uses Of Pharmaceutical Compositions
|
Oct, 2030
|
3
| |
|
EP3517539B1 |
14 Dec, 2022
|
Substituted Dimeric Quinazoline Derivative, Its Preparation And Its Use In Pharmaceutical Compositions For The Treatment Of Type I And Ii Diabetes
|
Jul, 2032
|
3
| |
|
EP2956483B1 |
27 May, 2020
|
Therapeutic And Diagnostic Target For Cancer Comprising Dll3 Binding Reagents
|
Feb, 2034
|
3
| |
|
EP2395983B1 |
08 Apr, 2020
|
Pharmaceutical Composition Comprising A Sglt2 Inhibitor, A Dpp-Iv Inhibitor And Optionally A Further Antidiabetic Agent And Uses Thereof
|
Feb, 2030
|
3
| |
|
EP2451445B1 |
03 Apr, 2019
|
Process For Drying Of Bibw2992, Of Its Salts And Of Solid Pharmaceutical Formulations Comprising This Active Ingredient
|
Jul, 2030
|
3
| |
|
EP3362055B1 |
18 Jan, 2023
|
Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Myopathy
|
Oct, 2036
|
2
| |
|
EP2566469B1 |
21 Dec, 2022
|
Combination Therapy
|
May, 2031
|
2
| |
|
EP2849754B1 |
14 Sep, 2022
|
A Xanthine Derivative As Dpp-4 Inhibitor For Use In The Treatment Of Sirs And/Or Sepsis
|
May, 2033
|
2
| |
|
EP2729151B1 |
31 Mar, 2021
|
Pharmaceutical Composition, Methods For Treating And Uses Thereof
|
Jul, 2032
|
2
| |
|
EP2640371B1 |
08 Jan, 2020
|
Vasoprotective And Cardioprotective Antidiabetic Therapy
|
Nov, 2031
|
2
| |
|
EP2504002B1 |
09 Oct, 2019
|
Treatment Of Genotyped Diabetic Patients With Dpp-Iv Inhibitors Such As Linagliptin
|
Nov, 2030
|
2
| |
|
EP1720663B2 |
15 Sep, 2021
|
Atomiser Comprising Coding Means
|
Feb, 2025
|
1
| |
|
EP2819669B1 |
21 Apr, 2021
|
Novel Propellant-Gas-Containing Tiotropium Formulation
|
Feb, 2033
|
1
| |
|
EP3288561B1 |
31 Mar, 2021
|
Methods And Pharmaceutical Compositions Comprising A Sglt2 Inhibitor For Treating Or Improving Erectile Dysfunction
|
Apr, 2036
|
1
| |
|
EP3370810B1 |
18 Dec, 2019
|
System With Nebulizer And Container
|
Nov, 2036
|
1
| |
|
EP2190434B1 |
17 Apr, 2019
|
Purin Derivatives For Use In The Treatment Of Fab-Related Diseases
|
Aug, 2028
|
1
| |
|
EP1940349B1 |
14 Feb, 2018
|
Aerosol Formulation For The Inhalation Of Beta Agonists
|
Oct, 2026
|
1
| |
